Financial Performance - Catheter Precision, Inc. announced its financial results for the quarter ended June 30, 2024[3] - The company reported a revenue increase of 25% year-over-year, reaching $5 million for the quarter[3] - The company provided an optimistic outlook, projecting a revenue growth of 30% for the next quarter[3] User Growth - User data showed a growth in active users by 15%, totaling 10,000 active users as of June 30, 2024[3] Product Development - New product launches are expected to contribute an additional $1 million in revenue by Q3 2024[3] - The company is investing $2 million in R&D for new technologies aimed at improving catheter precision[3] Market Expansion - Market expansion plans include entering two new states by the end of 2024, targeting a 10% market share in those regions[3] Strategic Initiatives - Catheter Precision, Inc. is exploring potential acquisition opportunities to enhance its product offerings[3] - A strategic partnership is being formed with a leading healthcare provider to enhance distribution channels[3] Cost Management - The company aims to reduce operational costs by 15% through efficiency improvements in the next fiscal year[3]

Product Development and Regulatory Approvals - The VIVO System has been utilized in over 1,000 procedures in the U.S. and EU by more than 30 physicians, with no reported device-related complications[154]. - The LockeT product received FDA registration in February 2023, with initial shipments to distributors beginning shortly thereafter[156]. - CE Mark approval for LockeT is expected in the second half of 2024, allowing for initial international shipments to distributors[156]. - The company has initiated clinical studies for LockeT, aimed at demonstrating faster wound closure and lower healthcare costs[157]. - The VIVO System has received regulatory clearance as a pre-procedure planning tool for patients with structurally normal hearts undergoing ablation treatment[154]. - The company aims to establish VIVO as an integral tool for cardiac electrophysiologists, enhancing procedural success and reducing complications[153]. - The company has shifted focus to cardiac electrophysiology products following the merger with Old Catheter[152]. - The company plans to continue developing innovative medical technologies in the field of cardiac electrophysiology[153]. Financial Performance and Cash Flow - Revenues for the three months ended June 30, 2024 decreased by approximately $3 thousand to $93 thousand compared to the same period in 2023, while revenues for the six months ended June 30, 2024 decreased by approximately $6 thousand to $175 thousand[177]. - Cost of revenues increased by approximately $9 thousand for the three months ended June 30, 2024, and by approximately $4 thousand for the six months ended June 30, 2024, primarily due to order fulfillment charges for the LockeT product[178]. - Selling, general and administrative expenses increased by approximately $1.3 million for the three months ended June 30, 2024, but decreased by approximately $6.3 million for the six months ended June 30, 2024, mainly due to reductions in salaries and legal fees[179][180]. - Research and development expenses decreased by approximately $0.1 million for the three months and $0.3 million for the six months ended June 30, 2024, primarily due to reduced regulatory affairs expenditures[181]. - No impairment charges were incurred for the three and six months ended June 30, 2024, following significant impairment charges of $4.8 million and $60.9 million recognized in the same periods of 2023[183][182]. - The change in fair value of royalties payable decreased by $6.1 million for the three months and $6.2 million for the six months ended June 30, 2024, compared to the same periods in the prior year[184]. - As of June 30, 2024, the company had cash and cash equivalents of approximately $16 thousand and an accumulated deficit of approximately $282.6 million[186]. - Net cash used in operating activities for the six months ended June 30, 2024 was approximately $3.6 million, compared to $16.9 million for the same period in 2023[189]. - The company expects operating losses and negative cash flows to continue, raising substantial doubt about its ability to continue as a going concern for the next year[188]. - The company is evaluating potential means of raising cash through future capital transactions and additional bridge loans to fund operations[187]. Stock and Equity Transactions - A reverse stock split was approved on July 3, 2024, reducing authorized common stock to 30 million shares[158]. - The company raised approximately $1.3 million in gross proceeds from a warrant inducement offer, with placement agent fees of about $0.2 million, representing 8.0% of the gross proceeds[161]. - A private placement on March 23, 2023, resulted in an aggregate purchase price of approximately $8.0 million, consisting of 497,908 Class A Units and 4,501,060 Class B Units[162]. - The company approved the issuance of 199,359 shares of common stock upon conversion of Series X Convertible Preferred Stock, with further conversions expected until at least July 9, 2024[166]. - The company has a 2023 Equity Incentive Plan that allows for the grant of options and restricted stock, with 46,000 options outstanding as of June 30, 2024[170]. Royalties and Future Obligations - The company will pay a total royalty of approximately 12% of net sales of LockeT, starting from the first commercial sale until December 31, 2035[197]. - A 5% royalty on net sales of LockeT will be paid up to $1 million, after which a 2% royalty will apply until total cumulative royalties reach $10 million, contingent on a U.S. patent being granted[198]. Accounting and Compliance - The company is currently reviewing the impact of ASU 2023-07 on its consolidated financial statements, which requires enhanced segment expense disclosures effective for fiscal years beginning after December 15, 2023[200]. - The company is required to adopt ASU 2023-09 for the fiscal year 2025, which mandates improved income tax disclosures, effective for annual periods beginning after December 15, 2024[201]. Product Sales and Market Presence - The company recognized its first sales of the LockeT product during the three months ended June 30, 2024, with revenue recognized upon delivery[174]. - Approximately 35% and 38% of the company's sales for the three and six months ended June 30, 2024, respectively, were derived from customers outside the United States[174]. - The company has shifted its focus to Old Catheter's product lines, primarily in cardiac electrophysiology, following the cessation of the legacy DABRA laser operations[171]. - The VIVO System, one of the company's primary products, offers 3D cardiac mapping and revenue is recognized upon delivery[172]. - The company has not commenced sales of the AMIGO System, which is subject to sales-based royalties upon successful commercialization[199].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K _________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 _________________ Catheter Precision, Inc. (Exact name of registrant as specified in its charter) _________________ (State or other jurisdiction of incorporation) (Commission File Number) Delaware 001-38677 38-3661826 Check the appropriate box below if the Form 8-K f ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File No. 001-38677 Catheter Precision, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 38-3661826 (I.R.S. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K __________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-38677 Catheter Precision, Inc. (Exact name of Registrant as specified in its charter) __________________________ Del ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File No. 001-38677 Catheter Precision, Inc. (Exact name of registrant as specified in its charter) Delaware 38-3661826 (State or other jurisdiction of incorporation or organization) (I. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File No. 001-38677 Catheter Precision, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 38-3661826 (I.R.S. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File No. 001-38677 Ra Medical Systems, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or 1670 Highway 160 West, Suite 205 Fort Mil ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-38677 Ra Medical Systems, Inc. (Exact name of Registrant as specified in its charter) Delaware 38-3661826 (State or other jurisdiction of incor ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-38677 Ra Medical Systems, Inc. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or ...